key: cord-0256219-2yujuk9p
authors: Yahalom-Ronen, Y.; Erez, N.; Fisher, M.; Tamir, H.; Politi, B.; Achdout, H.; Melamed, S.; Glinert, I.; Weiss, S.; Cohen-Gihon, I.; Israely, O.; Izak, M.; Mandelboim, M.; Caraco, Y.; Madar-Balakirski, N.; Mechaly, A.; Shinar, E.; Cohen, D.; Beth-Din, A.; Zvi, A.; Marcus, H.; Israely, T.; Paran, N.
title: Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera
date: 2021-11-24
journal: nan
DOI: 10.1101/2021.11.22.21266673
sha: 11494f5affbb475cf6bfe50b25ff17edb9d95a52
doc_id: 256219
cord_uid: 2yujuk9p

BriLife(R) (rVSV- {Delta}G-spike) is a SARS-CoV-2 vaccine candidate based on vesicular stomatitis virus (VSV) platform. We show that sera from BriLife(R) vaccinees maintain neutralization capacity against alpha, beta, gamma and delta SARS-CoV-2 variants. BriLife(R) spontaneously-acquired spike mutations, corresponding with key SARS-CoV-2 variants mutations, may contribute to its efficacy against SARS-CoV-2 variants.

Coronavirus-2 (SARS-CoV-2) vaccine candidate, based on the Vesicular Stomatitis Virus (VSV) platform, in which the VSV glycoprotein (G) was replaced by the SARS-CoV-2 spike protein (S) to make an rVSV-ΔG-spike [1] .

Since the emergence of the original SARS-CoV-2, several variants have been described, including variants that appeared in the United Kingdom (alphaor B.1.1.7), South Africa We tested blinded serum samples from two cohorts of participants in a BriLife® phase II clinical trial (ClinicalTrials.gov -NCT04608305) two weeks following intramuscular prime-boost vaccination for their ability to neutralize SARS-CoV-2 variants alpha, beta, gamma or delta. Inclusion criteria were negative SARS-CoV-2 nucleocapsid binding (data not shown) and positive SARS-CoV-2 neutralization response against the original virus.

Nine tested sera ("cohort 1", Table S1 ) efficiently neutralized the original virus, as well as the gamma variant, with mean titers of 246 and 357, respectively (0.7-fold change, Fig. 1c , Table S1 ). Nearly all tested sera neutralized alpha (8/9 samples) and beta (7/9 samples) variants, with mean titers of 163 and 103, respectively (1.5-fold reduction relative to original virus, and 2.4-fold reduction, Fig. 1a -b, Table S1 ).

In recent months, delta variant of concern (VOC) has become dominant worldwideexhibiting increased transmissibility, apparent immune escape [2] , and breakthrough infections in vaccinated individuals [3] . We therefore tested another set of 11 vaccinees sera ("cohort 2", Table S2 ) for neutralization of both original virus and delta VOC. Of 11 tested sera which neutralized the original virus, ten also neutralized the delta variant, with no significant difference in neutralization titers (Fig. 1d , Table S2 ).

Immunity to surface antigens of viral vectored-based vaccines (e.g. adenovirus-based platforms) might hamper their efficacy upon repeated usage. Replacement of VSV-G surface antigen with the antigen of interest reduces the risk of vector immunity [4] . We show that vector immunity was not significantly induced following BriLife® vaccination (Fig. 1e, Table S3 ), excluding the risk of reduced vaccine efficacy upon repeated vaccinations.

We also compared neutralization capacity of 9 convalescent sera from early pandemic infections ("cohort 3", Table S4 ) between the original virus and alpha, beta, gamma or delta variants. We show no significant difference in neutralization titers of the original virus and that of alpha, beta or gamma variants ( Fig. 2a -c, Table S4 ). However, we do see a significant 3.8-fold reduction in neutralization titers of convalescent sera against delta VOC compared to the original virus (Fig. 2d , Table S4 ).

Amino acid substitutions in SARS-CoV-2 emerging variants might compromise the protection afforded by vaccines and therapeutic antibodies. Currently approved vaccines use a modified version of the spike sequence of the original Wuhan virus [5] [6] [7] .

Convalescent sera tested in the current study was obtained from individuals infected at early stages of the pandemic, hence exposed to the original virus.

Development of BriLife® was accompanied by spontaneous acquisition of several mutations, some of which are at the spike protein at sites of major importance to antibodymediated immunity, such as N501 and E484 located in the receptor binding domain (RBD)

[1]. An additional mutation is R685G at the RRAR multibasic furin cleavage site, located at the junction of the receptor-binding (S1) and fusion (S2) domains of the spike protein

[1]. With that mentioned, final vaccine batches are genetically stable. BriLife® abovementioned mutations are similar or identical to some of the key naturally-occurring mutations in SARS-CoV-2 variants. The N501Y substitution is found in alpha, beta and gamma variants [8] . E484 is mutated in BriLife® to aspartic acid to form E484D. In beta and gamma variants, E484 is mutated to Lysine (K, E484K). E484K, E484D, E484A and E484G substitutions were shown to escape neutralization by convalescent human sera [8] ,

further consolidating the role of E484 in antibody binding. N501Y as a single mutation does not significantly impair sensitivity to vaccine-induced antibodies [9] . However, combination of E484K, N501Y and additional mutations such as K417N or K417T found in beta and gamma variants, respectively, was shown to significantly affect neutralization capacity in sera of convalescent or vaccinated individuals [10] . We suggest that the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint aforementioned BriLife® mutations might provide an advantage in combating SARS-CoV-2 variants.

As for the furin cleavage site, the leading proline residue P681 located just before the RRAR multibasic motif is replaced by Histidine at alpha variant (P681H) and by Arginine in delta variant (P681R). This region is of major importance to transmissibility and spreading of SARS-CoV-2 [8] . Whether the spontaneously acquired R685G mutation of BriLife® have a beneficial effect on vaccine efficacy, specifically against alpha and delta, awaits further investigation.

There is a major concern regarding the ability of vaccines to protect against SARS-CoV-2 variants. Neutralization titers against variants following two-dose vaccination with BNT162b2 , mRNA-1273 or ChAdOx1 nCoV-19 were reported, showing for most only a minor reduction in alpha neutralization, but a strong reduction in beta and gamma neutralization [11] , while others report no significant reduction in vaccine efficacy against the gamma variant [10, 12, 13 ]. An overall reduction in neutralization potential has been reported against the beta variant ranging between ~2-30-fold, depending on the report [8, 10, 13, 14] . For delta variant, some report a modest reduction in the effectiveness of twodose vaccines compared to the alpha variant or to the original virus. An overall reduction ranges between ~2-11 fold [12] [13] [14] [15] .

A significant reduction in neutralization potential of convalescent sera from early pandemic stages against alpha, beta, gamma or delta variants was also reported [11, 13, [16] [17] [18] .

Overall, it appears that the beta is the most resistant variant to neutralization either by convalescent sera, currently available vaccines, or BriLife® vaccination. Recent crossneutralization data from convalescent sera from different pandemic waves shed light on the possible contribution of specific Spike mutations to protection from variants [11] and raise the need for updated vaccines. Limitation of this brief report is the relatively small number of serum samples tested.

We suggest that spontaneously-acquired mutations such as N501Y and E484D, that occurred during BriLife® development and correspond to naturally-occurring mutations of All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint SARS-CoV-2 variants, may increase the potential of BriLife® to maintain effectiveness against current SARS-CoV-2 variants, and potentially against future VOC.

Taken together, our data indicates that BriLife®-induced antibodies maintain neutralizing potential against all tested variants, and most importantly against the delta VOC. . Samples below LOD were assigned a value of 10 (half of the LOD). Statistical significance was determined by one-way ANOVA nonparametric test with Kruskal-Wallis test. Data is presented as mean ± SEM. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint Table S1 . Neutralizing titers (NT50) of BriLife® vaccinees against SARS-CoV-2 original virus, variants alpha, beta, and gamma (cohort 1). Samples that were below LOD were assigned a value of 10 (half of the LOD). preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint Table S2 . Neutralization titers (NT50) of BriLife® vaccinees against SARS-CoV-2 original virus and delta variant of concern (cohort 2). Samples that were below LOD were assigned a value of 10 (half of the LOD). preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint Table S3 . Neutralization titers (NT50) of BriLife® vaccinees against rVSV-WT (Indiana serotype) at time zero (T0), 28 days post 1 st vaccination (P) and two weeks following 2 nd vaccination (P+B). Samples that were below LOD were assigned a value of 10 (half of the LOD). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint Table S4 . Neutralizing titers (NT50) of convalescent sera against SARS-CoV-2 original virus, variants alpha, beta, gamma and delta (cohort 3). Samples that were below LOD were assigned a value of half of the LOD. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. [15] . Alpha variant (B.1.1.7, GISAID All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Vero E6 cells were seeded in 12-well plates. Sera from BriLife® vaccinees or COVID-19 convalescent patients were heat inactivated (HI) (56 °C for 30 min), then diluted in twofold serial dilutions (between 1:20 and 1:1280) in 300 µl of infection medium, mixed with 300 µl of either 300 pfu/ml of SARS-CoV-2 original virus, each variant (alpha, beta, gamma or delta), or rVSV-WT, and incubated at 37 °C, 5% CO2 for 1 h. Serum-virus mixtures were added in duplicates to the cells for 1 h at 37 °C. Virus samples (original virus, alpha, beta, gamma, delta variant, or rVSV-WT) without serum served as controls for each respective virus-serum mixture. Two milliliters overlay were added to each well and plates were incubated at 37 °C, 5% CO2 for 24 h (for rVSV-WT), 72 h (for SARS-CoV-2 original virus, beta, gamma or delta variant) or 96 h (for alpha variant). Following incubation, overlay was aspirated and the cells were fixed and stained with 1 ml/well of crystal violet solution. The plaques in each well were numbered, and the serum dilution that neutralizes 50% of the virions (NT50) was calculated using GraphPad Prism 6 software (GraphPad Software Inc.).

Data were analyzed with GraphPad Prism 6 software. Exact p values are provided for each analysis. Statistical significance for SARS-CoV-2 variants neutralization were determined by unpaired t-test, p values are indicated. Statistical significance for VSV vector immunity was determined by one-way ANOVA nonparametric test by Kruskal-Wallis test.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.22.21266673 doi: medRxiv preprint

14. Noori